FDA Grants Approval for Lorazepam ANDA200542 by Rising
The FDA has granted approval for the ANDA200542 application for Lorazepam submitted by Rising.
Published: August 9, 2026
Updated: August 9, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Anxiolytic
Asset: Lorazepam
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Lorazepam
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Lorazepam ANDA200542 by Rising is significant as it strengthens their foothold in the anxiolytic market. This development necessitates a strategic response from competitors to maintain their market share and address potential shifts in consumer preference.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of Lorazepam by Rising and any competitive responses from other manufacturers.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.